Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.995 USD | +1.27% | +56.79% | +26.72% |
06-06 | Top Premarket Gainers | MT |
04-25 | Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.72% | 4.65M | |
+52.52% | 59.28B | |
+41.87% | 40.94B | |
-6.23% | 40.17B | |
-5.56% | 28.69B | |
+10.75% | 26.63B | |
-22.84% | 18.89B | |
+30.34% | 12.46B | |
+1.31% | 12.42B | |
+25.21% | 12.26B |
- Stock Market
- Equities
- VRAX Stock
- News Virax Biolabs Group Limited
- Virax Biolabs Says US FDA Grants Emergency Use Authorization for COVID-19 Rapid Antigen Test